Transduction of an HLA-DP4–restricted NY-ESO-1–specific TCR into Primary Human CD4+ Lymphocytes
- 1 July 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Immunotherapy
- Vol. 29 (4) , 398-406
- https://doi.org/10.1097/01.cji.0000203082.20365.7f
Abstract
CDNAs encoding functional T cell receptor (TCR) α and β chains from a CD4+ T cell line (SG6) generated by repeated stimulation of a melanoma patient's peripheral blood mononuclear cells with HLA-DP4–restricted, NY-ESO-1–specific peptide p161-180 were cloned using a 5′rapid amplification of cDNA end method. Three different TCR α chains and 7 TCR β chains were found among the 84 α and 162 β cDNA clones tested. By screening different combination of the α/β chains using RNA electroporation, TRAV9-1 (Vα22.1) and TRBV20-1 (Vβ2) were found to be the functional pair in line SG6. Antibody blocking experiments confirmed that the specificity of TRAV9-1/TRBV20-1 mRNA-transfected T cells were CD4 dependent and HLA-DP4 restricted. A retroviral vector expressing both TRAV9-1 and TRBV20-1 was constructed and used for transduction of OKT3-stimulated peripheral blood lymphocytes from melanoma patients. TCR-transduced CD4 T cells were capable of recognizing peptide-pulsed antigen-presenting cells (Epstein-Barr virus transformed B-cells, dendritic cells, and peripheral blood mononuclear cells), and protein-pulsed dendritic cells. Transduced cells were also capable of proliferation upon peptide stimulation and recognized peptide concentrations that were recognized by the parental line (0.2 μM). In contrast to SG6, which could not recognize human tumors, TCR-transduced CD4 T cells could specifically recognize NY-ESO-1/HLA-DP4–expressing melanoma cells. Major histocompatibility complex class II TCR-transduced CD4 T cells provides an alternative source of tumor antigen-specific T cells for adoptive immunotherapy of cancer patients.Keywords
This publication has 55 references indexed in Scilit:
- Multiple survival signals are delivered by dendritic cells to naive CD4+ T cellsEuropean Journal of Immunology, 2005
- Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic MelanomaJournal of Clinical Oncology, 2005
- Cooperation of Human Tumor-Reactive CD4+ and CD8+ T Cells after Redirection of Their Specificity by a High-Affinity p53A2.1-Specific TCRImmunity, 2005
- A simple method to cure established tumors by inflammatory killing of normal cellsNature Biotechnology, 2004
- CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curativeEuropean Journal of Immunology, 2004
- A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic MelanomaJournal of Immunotherapy, 2002
- Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte ResponsesThe Journal of Experimental Medicine, 2001
- Proliferating dendritic cell progenitors in human blood.The Journal of Experimental Medicine, 1994
- Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.The Journal of Experimental Medicine, 1982
- A Disquisition on Suppressor T CellsImmunological Reviews, 1975